Entering text into the input field will update the search result below

Vtv Therapeutics perks up ahead of TTP399 data

  • VTv Therapeutics' (NASDAQ:VTVT) two late-breaking abstracts reinforcing the potential of TTP399 as an oral adjunctive therapy in type 1 diabetes will be presented at the American Diabetes Association’s 80th Scientific Sessions, which is being held virtually, June 12–16, 2020.
  • Details of the virtual presentations which will provide full clinical study data from that trial are as follows:
  • Poster I Title: “The Simplici-T1 Trial: Glucokinase Activator TTP399 Improves Glycemic Control in Patients with Type 1 Diabetes”, and;
  • Poster II Title: “The Simplici-T1 Trial: Relationship between Glycemic Control and Insulin Dose”.
  • Shares are up 8% premarket.

Recommended For You

More Trending News

About VTVT Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
VTVT--
vTv Therapeutics Inc.